Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H38N4O7 |
| Molecular Weight | 554.6346 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=NC3=C(CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N5C[C@@H](C[C@H]5C(O)=O)O3)C(C)(C)C)N=C2C=C1
InChI
InChIKey=IVROMYPOGKZNLP-FDOFPDFBSA-N
InChI=1S/C29H38N4O7/c1-29(2,3)24-26(34)33-15-18(14-22(33)27(35)36)39-25-20(30-19-11-10-17(38-4)13-21(19)31-25)9-7-5-6-8-16-12-23(16)40-28(37)32-24/h10-11,13,16,18,22-24H,5-9,12,14-15H2,1-4H3,(H,32,37)(H,35,36)/t16-,18-,22+,23-,24-/m1/s1
MK-5172 (Grazoprevir) intermediate. Grazoprevir is a second generation NS3/4A protease inhibitor approved in the EU and the USA for the treatment of hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients in combination with elbasvir (C virus (HCV) NS5A inhibitor) as the fixed-dose combination product Zepatier with or without ribavirin.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
46930991
Created by
admin on Mon Mar 31 21:16:56 GMT 2025 , Edited by admin on Mon Mar 31 21:16:56 GMT 2025
|
PRIMARY | |||
|
RU4QU6O6X6
Created by
admin on Mon Mar 31 21:16:56 GMT 2025 , Edited by admin on Mon Mar 31 21:16:56 GMT 2025
|
PRIMARY | |||
|
1206524-85-7
Created by
admin on Mon Mar 31 21:16:56 GMT 2025 , Edited by admin on Mon Mar 31 21:16:56 GMT 2025
|
PRIMARY | |||
|
DTXSID20152954
Created by
admin on Mon Mar 31 21:16:56 GMT 2025 , Edited by admin on Mon Mar 31 21:16:56 GMT 2025
|
PRIMARY |
